Cytochrome P450 2C9 (CYP2C9) Genotyping
The cytochrome P450 (CYP450) enzymes catalyze the oxidation of many drugs and chemicals in our body. CYP450 is a large enzyme family mostly found in the liver. Since these enzymes have more than 50 isoenzymes (variations), their activity may vary from person to person. Individual differences of cytochrome P450 activity can result in total absence or decreased metabolism of certain drugs to ultrafast or increased metabolism of drugs. This can lead to adverse drug reactions or a lack of therapeutic effect under standard therapy conditions.
CYP2C9 is gene 9 within the C subfamily of the two families of the CYP450 superfamily. It metabolizes 16% of all prescribed drugs, such as many antidepressants, angiotensin II blockers, glipizide, phenytoin, and S-warfarin. Genetic polymorphisms (gene variation) of CYP2C9 could be used to predict the altered enzyme activity and address the potential effects of metabolized drugs. Individuals exhibiting the most common variant alleles of 2C9, *2 or *3 (Poor Metabolizers - PM) are at increased risk of metabolizing a drug poorly or not at all. This phenotype is found in approximately 35% of the Caucasian population. 2C9 *4 is found solely in the Japanese population while 2C9 *5 and *6 (Intermediate Metabolizers - IM) can be found in all populations.
Deficient activity of 2C9 may result in reduced or lack of therapeutic benefit and the possibility of adverse drug reactions due to metabolite buildup in the body. The combinations of the alleles in this group determine the level of metabolism of the drugs. This should be considered prior to initiating or modifying treatment or supplementing with additional drugs. The metabolism of drugs is also influenced by ethnicity, diet, and other medications. All factors should be considered prior to initiating new therapy. This test identifies five of the most common variants of CYP2C9 (2C9 *2, 2C9 *3, 2C9 *4, 2C9 *5 and 2C9 *6) which cover more than 99% of gene variation associated with this enzyme.
- Determining therapeutic strategy for therapeutics that are metabolized by the CYP450 2C9 gene product, specifically \2, \3, \4, \5, \*6 variants
- Monitor and manage antidepressant drug therapy
Results are usually reported as normal metabolizers (NM), intermediate metabolizers (IM), and poor metabolizers (PM). This varies depending on the technology and the laboratory that performs the testing. The wild-type allele of the CYP2C9 gene is designated CYP2C9*1. Homozygous wild-type individuals have a normal metabolizer phenotype (NM).
- Normal metabolizers (NM) have no gene variation, are normal metabolizers. This phenotype include two active CYP2C9 alleles
- Intermediate metabolizers (IM) contain one variant and one normal CYP2C9 allele. Therefore, activity of this enzyme is decreased and the phenotypes may require lower than average drug dose for optimal therapeutic response
- Poor metabolizers (PM) have two or more gene variants and the enzyme activity is significantly decreased. Phenotypes with these variants have increased risk of drug-induced side effects due to significant decreased enzyme activity. An example is the drug Plavix
The most common poor metabolizer phenotypes have been identified as CYP2C9 *2 and CYP2C9 *3. Variants CYP2C9 *2 (C430T) and CYP2C9 *3 (A1075C) each differ from the normal CYP2C9 *1 by a single nucleotide substitution, which leads to impaired enzyme activity. If genetic polymorphisms of CYP2C9 (*2, *3, *4, *5, *6) are present, this would predict altered enzyme activity and address the potential effects of metabolized drugs. Change in the therapy should be executed.
The following is a list of major therapeutic classes with drugs that are substantially metabolized by CYP2C9:
NSAIDs: diclofenac, ibuprofen, lornoxicam, meloxicam, S-naproxen→Nor, piroxicam, suprofen Oral Hypoglycemic Agents: tolbutamide, glipizide Angiotensin II Blockers: losartan, irbesartan Sulfonylureas: glyburide, glibenclamide, glipizide, glimepiride, tolbutamide, amitriptyline, celecoxib, fluoxetine, fluvastatin, glyburide, nateglinide, phenytoin-4-OH2, rosiglitazone, tamoxifen, torsemide, S-warfarin
The following is a list of major inhibitors that compete with other drugs for a particular enzyme thus affecting the optimal level of metabolism of the substrate drug which in many cases affect the individual's response to that particular medication, e.g. making it ineffective.
A Strong inhibitor is one that causes a > 5-fold increase in the plasma AUC values or more than 80% decrease in clearance. This include: fluconazole
A Moderate inhibitor is one that causes a > 2-fold increase in the plasma AUC values or 50-80% decrease in clearance. This include: amiodarone, fenofibrate, fluvastatin, fluvoxamine, isoniazid, lovastatin, phenylbutazone, probenicid, sertraline, sulfamethoxazole, sulfaphenazole, teniposide
A Weak inhibitor is one that causes a > 1.25-fold but < 2-fold increase in the plasma AUC values or 20-50% decrease in clearance such as voriconazole and zafirlukast.
CYP2C9 \*1/\*1 (Normal metabolizers)
Blood (EDTA), buccal swab, saliva.
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- Arch Pharm Res. 2011 Nov;34(11):1799-816. [PMID: 22139682]
- Circulation. 2010; 121(4):512-8. [PMID: 20083681]
- N Engl J Med. 2009; 360(4):363-75. [PMID: 19106083]
- Pharmacogenomics. 2009; Nov;10(11):1799-817. [PMID: 19891556]
- Circulation. 2010; 121(4):512-8. [PMID: 20083681]
- N Engl J Med. 2009; 360(4):363-75. [PMID: 19106083]